$VEEV

Tom Schwenger, former President and Chief Customer Officer of Veeva Systems, has been appointed CEO of Omnicom Health's marketing business. He will oversee global marketing agencies and drive growth, innovation, and AI adoption. Schwenger previously tripled Veeva's revenue and led Accenture's life sciences practice. Omnicom (NYSE: OMC) is a leading marketing and sales company.

Amgen will expand its partnership with Veeva Systems by deploying Veeva Vault CRM globally. The AI-powered platform aims to enhance engagement with healthcare professionals and accelerate therapy delivery. Amgen's CIO Scott Skellenger stated this will improve speed and agility in bringing new therapies to patients. Veeva's Matt Farrell highlighted the role of Vault CRM in supporting Amgen's global launches. Veeva serves over 1,500 life sciences companies.

Veeva Systems Inc.'s average stock price target increased from $299.15 to $301.08, with a range of $180 to $360, according to 26 analysts. This implies a 7% downside from the Oct. 22 closing price. The consensus rating remains 'Buy' among 32 analysts.

Veeva Systems (VEEV) raised its fiscal 2027 earnings forecast to $9.21 per share and revenue to $3.68-$3.69B, up from prior estimates. The stock gained 30.7% since the announcement, outperforming the S&P 500. Q2 revenue was $928M, exceeding guidance. The stock is 56.0% above its 200-day average, with a strong upward trend.

Jonathan Faddis, SVP and General Counsel of Veeva Systems (VEEV), sold 5,198 shares on 2026-10-14 at $299.72 per share, reducing his holdings to 4,130 shares. VEEV has a market cap of $50.25 billion and a P/E ratio of 51.06. Insider sales have been frequent, but institutional investors show strong interest.

Faddis Jonathan (SVP, Gen. Counsel, Secretary) sold 5,198 shares of VEEVA SYSTEMS INC (VEEV) at an average of $299.72 ($298.19–$300.14, $1.56M total) across 3 trades on 2026-10-14 under a Rule 10b5-1 trading plan.

Analysts updated ratings and price targets for several companies. Ebay (EBY) was upgraded to buy, while Workday (WDAY) was downgraded to sector weight. Fair Isaac (FICO) and Crowdstrike (CRWD) saw target price changes. Other affected firms include Ccc Intelligent Solutions (CCCS), Eastman Chemical (EMN), Jpmorgan Chase (JPM), and Rocket Lab (RKLB).

Oppenheimer reiterated an Outperform rating and $325 price target on Veeva Systems (VEEV), citing strong R&D growth and broad-based demand. VEEV's Q2 fiscal 2027 revenue of $928M beat estimates, leading multiple analysts to raise price targets. The company's guidance was driven by execution and improved visibility, with Vault CRM migrations operating near peak levels.

Veeva Systems (VEEV) stock rose 2.8% after expanding its partnership with IQVIA, which adopted Veeva's clinical operations software. The company reported Q2 revenue of $928M, up 17.6% YoY, beating estimates. VEEV raised full-year revenue guidance to $3.68B and adjusted earnings outlook to $9.21 per share. The stock is up 37% YTD and hit a 52-week high.

Unity (NYSE:U) beat estimates, stock up 32.1%. Upstart (NASDAQ:UPST) reported 41.7% revenue growth but missed guidance, stock down 20.5%. Dolby (NYSE:DLB) revenue fell 3.3%, stock up 13.4%. Doximity (NYSE:DOCS) revenue up 7.3%, stock up 47.6%. Market focus shifted from AI to geopolitics.